Top of this page
Skip navigation, go straight to the content

Newsroom Press Releases

Transparency notifications BlackRock, Inc.

  • 2 notifications referring to situation on 2 October and 3 October 2018
  • Threshold crossed: 5%
  • Latest holding: 4.998% 

Brussels (Belgium), 5 October 2018 – 20:00 (CEST) – regulated information

1. Summary of the notifications

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received 2 transparency notifications from BlackRock, Inc. (having its registered office at 55 East 52nd Street, New York, NY, 10055, U.S.A.), dated 3 October and 4 October 2018 respectively.

In the first notification BlackRock, Inc. has notified that, following an acquisition of UCB shares with voting rights and a disposal of equivalent financial instruments by its affiliates, its total holding in UCB SA/NV has increased and has crossed the 5% threshold on 2 October 2018. 

In the second notification, BlackRock, Inc. has notified that, following a disposal of UCB shares with voting rights and of equivalent financial instruments by its affiliates, its total holding in UCB SA/NV has decreased and has crossed downwards the 5% threshold on 3 October 2018. 

On 2 October 2018, BlackRock, Inc. (taking into account the holding of its affiliates) owned 9 314 285 UCB shares with voting rights (versus 9 160 827 shares in its previous notification), representing 4.79% of the total number of shares issued by the company (194 505 658) (versus 4.71% in its previous notification) as well as 523 694 equivalent financial instruments (versus 533 251 in its previous notification) representing 0.27% of the total number of shares issued by the company (same percentage as in its previous notification). 

On 3 October 2018, BlackRock, Inc. (taking into account the holding of its affiliates) owned 9 204 553 UCB shares with voting rights, representing 4.73% of the total number of shares issued by the company, as well as 518 658 equivalent financial instruments, representing 0.27% of the total number of shares issued by the company.

2. Content of the notifications

2.1 The information mentioned hereafter was identical in both notifications:

  • Reason for the notification: Acquisition or disposal of voting securities or voting rights.
  • Notification by: A parent undertaking or a controlling person.
  • Threshold crossed (in %): 5%
  • Denominator: 194 505 658.
  • Chain of controlled undertakings through which the holding is effectively held:

Please see the full chain of control in the ‘Chain of Control’ tab.

2.2 The first transparency notification dated 3 October 2018 included the following specific information:

  • Persons subject to the notification requirement

 

  • Date on which the threshold is crossed: 2 October 2018.
  • Notified details:


 
 

  • Additional information

The disclosure obligation arose due to total holding in voting rights for BlackRock, Inc. going above 5%.

2.3. The second transparency notification dated 4 October 2018 includes the following specific information:

  • Persons subject to the notification requirement

 

  • Date on which the threshold is crossed: 3 October 2018.
  • Notified details:

 
  

 

  • Additional information

The disclosure obligation arose due to total holding in voting rights for BlackRock, Inc. going below 5%.

3. Further information 
This press release and the detailed transparency notifications are available on UCB SA/NV’s website via the following link.
An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV’s website via the following link.

Investor Relations
Antje Witte          
Investor Relations, UCB
T +32.2.559.94.14 antje.witte@ucb.com

Isabelle Ghellynck,
 Investor Relations, UCB
T+32.2.559.9588, isabelle.ghellynck@ucb.com 

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7 500 people in approximately 40 countries, the company generated revenue of € 4.5 billion in 2017. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news


Stay up-to-date on the latest news and information from UCB